logo
logo

Brii Biosciences Adds Us$100 Million To Advance Its Late-Stage Monoclonal Antibody Combination Therapy, Brii-196/Brii-198, For Non-Hospitalized Covid-19 Patients

Sep 07, 2021•about 4 years ago

Amount Raised

$100 Million

DurhamBiotechnology Research

Description

Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that the Company is committing an additional US$100 million to advance global regulatory filings and commercial efforts for its investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy, BRII-196/BRII-198 ("combination BRII-196/BRII-198").

Company Information

Company

Brii Biosciences

Location

Durham, North Carolina, United States

About

Brii Biosciences is a commercial stage biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.

Related People

0 contacts

No contacts found in Executives department

Try selecting a different department above

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech